ICER to review Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression
Healthcare cost watchdog to scrutinize Compass’s synthetic psilocybin, and Study links enhanced feelings of connection to lighter depression following psilocybin
The Institute for Clinical and Economic Review announced on Wednesday it will evaluate the clinical effectiveness and cost of Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depressiontreatment-resistant depressionDepression that has not improved enough after adequate courses of at least two antidepressant treatments.Open the glossary, with results to be discussed at the May 2027 meeting of the New England Comparative Effectiveness Public Advisory Council.
Key facts
- Kind of item
- Access and funding
- Compound
- Psilocybin
- Condition
- Depression
- Organisation
- Compass Pathways
- Jurisdiction
- United States
- Source
- The Microdose (UC Berkeley BCSP) (themicrodose.substack.com)
- Published
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: The Microdose (UC Berkeley BCSP) · themicrodose.substack.com
Connected to
- Kind of item
- Access and funding
- Compound
- Psilocybin
- Condition
- Depression
- Organisation
- Compass Pathways
- Jurisdiction
- United States